World Health Organization grade III meningiomas. A retrospective study for outcome and prognostic factors assessment

被引:25
作者
Champeaux, C. [1 ,2 ]
Jecko, V. [2 ]
机构
[1] Hop St Anne, Serv Neurochirurg, 1 Rue Cabanis, F-75014 Paris, France
[2] Hop Pellegrin, Serv Neurochirurg, F-33000 Bordeaux, France
关键词
WHO grade III meningioma; Malignant meningioma; Radiotherapy; Outcome; Prognostic factors; MALIGNANT MENINGIOMAS; RADIOTHERAPY; SURVIVAL; AKT1;
D O I
10.1016/j.neuchi.2016.05.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background. - To depict the outcome of patients with WHO grade III meningioma and identify factors that may influence the survival. Material and methods. - Between 1989 and 2007, a retrospective search identified 43 WHO grade III meningiomas after cases exclusion. Nine patients (39.5%) had a previous history of grade I or II meningioma. The patients underwent a total of 89 surgical resections and 83.7% received radiotherapy. Median follow-up was 7.4 years. Results. - At the end of the study, 35 patients were deceased (81.4%). One patient died of disseminated metastatic disease of a papillary meningioma. Median overall survival was 4.1 years, 95% CI [1.9, 8.3]. Overall survival probability at 1, 5 and 10 years were respectively: 81.4%, 95% CI [70.6, 93.9], 48.8%, 95% CI [36,66.3] and, 27.5%, 95% CI [16.9, 44.9]. In univariate Cox regression, a previous surgery for WHO grade I or II meningioma (HR=2.05, 95% CI [1.03, 4.07], P=0.04) and the mitosis count (HR=0.3, 95% CI [0.12, 0.79], P=0.02) were associated with the overall survival. However, neither macroscopic gross total resection (HR=0.87, 95% CI [0.4, 1.87], P=0.71), nor radiotherapy (HR=0.75, 95% CI [0.31, 1.83], P=0.53) was associated with an increased survival. Conclusion. - This series highlights the poor prognosis associate with the diagnosis of malignant meningioma. Patients with primary WHO grade III meningioma demonstrating less than 14 mitosis per 10 high power fields may live longer. We could not confirm the usefulness of complete resection and adjuvant radiotherapy. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:203 / 208
页数:6
相关论文
共 29 条
  • [1] Long-Term Outcome After Radiotherapy in Patients With Atypical and Malignant Meningiomas-Clinical Results in 85 Patients Treated in a Single Institution Leading to Optimized Guidelines for Early Radiation Therapy
    Adeberg, Sebastian
    Hartmann, Christian
    Welzel, Thomas
    Rieken, Stefan
    Habermehl, Daniel
    von Deimling, Andreas
    Debus, Juergen
    Combs, Stephanie E.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (03): : 859 - 864
  • [2] Extent of Resection and Overall Survival for Patients With Atypical and Malignant Meningioma
    Aizer, Ayal A.
    Bi, Wenya Linda
    Kandola, Manjinder S.
    Lee, Eudocia Q.
    Nayak, Lakshmi
    Rinne, Mikael L.
    Norden, Andrew D.
    Beroukhim, Rameen
    Reardon, David A.
    Wen, Patrick Y.
    Al-Mefty, Ossama
    Arvold, Nils D.
    Dunn, Ian F.
    Alexander, Brian M.
    [J]. CANCER, 2015, 121 (24) : 4376 - 4381
  • [3] Backer-Grondahl T, 2012, INT J CLIN EXP PATHO, V5, P231
  • [4] Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
    Brastianos, Priscilla K.
    Horowitz, Peleg M.
    Santagata, Sandro
    Jones, Robert T.
    McKenna, Aaron
    Getz, Gad
    Ligon, Keith L.
    Palescandolo, Emanuele
    Van Hummelen, Paul
    Ducar, Matthew D.
    Raza, Alina
    Sunkavalli, Ashwini
    MacConaill, Laura E.
    Stemmer-Rachamimov, Anat O.
    Louis, David N.
    Hahn, William C.
    Dunn, Ian F.
    Beroukhim, Rameen
    [J]. NATURE GENETICS, 2013, 45 (03) : 285 - 289
  • [5] CHAMPEAUX C, 2015, BRIT J NEUROSURG, P1
  • [6] Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO
    Clark, Victoria E.
    Erson-Omay, E. Zeynep
    Serin, Akdes
    Yin, Jun
    Cotney, Justin
    Oezduman, Koray
    Avsar, Timuin
    Li, Jie
    Murray, Phillip B.
    Henegariu, Octavian
    Yilmaz, Saliha
    Guenel, Jennifer Moliterno
    Carrion-Grant, Geneive
    Yilmaz, Baran
    Grady, Conor
    Tanrikulu, Bahattin
    Bakircioglu, Mehmet
    Kaymakcalan, Hande
    Caglayan, Ahmet Okay
    Sencar, Leman
    Ceyhun, Emre
    Atik, A. Fatih
    Bayri, Yasar
    Bai, Hanwen
    Kolb, Luis E.
    Hebert, Ryan M.
    Omay, S. Bulent
    Mishra-Gorur, Ketu
    Choi, Murim
    Overton, John D.
    Holland, Eric C.
    Mane, Shrikant
    State, Matthew W.
    Bilguevar, Kaya
    Baehring, Joachim M.
    Gutin, Philip H.
    Piepmeier, Joseph M.
    Vortmeyer, Alexander
    Brennan, Cameron W.
    Pamir, M. Necmettin
    Kilic, Tuerker
    Lifton, Richard P.
    Noonan, James P.
    Yasuno, Katsuhito
    Guenel, Murat
    [J]. SCIENCE, 2013, 339 (6123) : 1077 - 1080
  • [7] Atypical and malignant meningioma: outcome and prognostic factors in 68 irradiated patients
    Detti, Beatrice
    Scoccianti, Silvia
    Di Cataldo, Vanessa
    Monteleone, Eleonora
    Cipressi, Samantha
    Bordi, Lorenzo
    Pellicano, Gianni
    Gadda, Davide
    Saieva, Calogero
    Greto, Daniela
    Pecchioli, Guido
    Buccoliero, Annamaria
    Ceroti, Marco
    Ammannati, Franco
    Biti, Giampaolo
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2013, 115 (03) : 421 - 427
  • [8] WHO grade II and III meningiomas: a study of prognostic factors
    Durand, Anne
    Labrousse, Francois
    Jouvet, Anne
    Bauchet, Luc
    Kalamarides, Michel
    Menei, Philippe
    Deruty, Robert
    Moreau, Jean Jacques
    Fevre-Montange, Michelle
    Guyotat, Jacques
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2009, 95 (03) : 367 - 375
  • [9] Farol HY, 2015, ONCOLOGY WILLISTON P, V29
  • [10] A review of malignant meningiomas: diagnosis, characteristics, and treatment
    Hanft, Simon
    Canoll, Peter
    Bruce, Jeffrey N.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2010, 99 (03) : 433 - 443